Pipeline

MRT-6160 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader of VAV1, which in our in vitro studies has shown deep degradation of its target with no detectable effects on other proteins. VAV1, a Rho-family guanine nucleotide exchange factor, is a key signaling protein downstream of both the T- and B-cell receptors. VAV1 expression is restricted to blood and immune cells, including T and B cells. Preclinical studies have shown that targeted degradation of VAV1 protein via an MGD modulates both T- and B-cell receptor-mediated activity. This modulation is evident both in vitro and in vivo, demonstrated by a significant decrease in cytokine secretion, proteins vital for maintaining autoimmune diseases. Moreover, VAV1-directed MGDs have shown promising activity in preclinical models of autoimmune diseases and thus have the potential to provide therapeutic benefits in multiple systemic and neurological autoimmune indications, such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and dermatological disorders. Preclinical studies demonstrate MRT-6160 inhibits disease progression in in vivo autoimmunity models. Details about our study of “Oral MRT-6160 in a First-in-human Study in Healthy Subjects” can be found at ClinicalTrials.gov under identifier: NCT06597799

In October 2024 we entered into a global development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160.

NEK7 and aberrant NLRP3 inflammasome activation has been implicated in multiple inflammatory disorders, including gout, cardiovascular disease, neurologic disorders including Parkinson’s disease and Alzheimer’s disease, ocular disease, diabetes, obesity, and liver disease. NEK7 has been shown to be required for NLRP3 inflammasome assembly, activation and IL-1b and interleukin-18 (IL-18) release both in vitro and in vivo. MRT-8102 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) that targets NEK7 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In a non-human primate model, MRT-8102 potently, selectively, and durably degrades NEK7 and results in near-complete reductions of IL-1b following ex vivo stimulation of whole blood. MRT-8102 has shown a favorable profile in non-GLP toxicology studies.

MRT-2359 is a potent, selective, and orally bioavailable molecular glue degrader (MGD) that induces the interaction between the E3 ubiquitin ligase component cereblon (CRBN) and the translation termination factor GSPT1, leading to the targeted degradation of GSPT1 protein. The MYC transcription factors (c‑MYC, L-MYC, and N-MYC) are well-established drivers of human cancers that maintain high levels of protein translation, which is critical for uncontrolled cell proliferation and tumor growth. Our preclinical studies have shown that this addiction to MYC-induced protein translation creates a dependency on GSPT1. MRT-2359 exploits this vulnerability by inducing degradation of GSPT1, disrupting protein synthesis preferentially in MYC-driven cell lines and leading to anti-tumor activity in MYC-driven tumor models. A phase 1/2 clinical study aims to evaluate the safety, tolerability, and anti-tumor activity of MRT-2359. Details about our study of “Oral MRT-2359 in Selected Cancer Patients” can be found at ClinicalTrials.gov under identifier: NCT05546268.

Cyclin proteins play crucial roles in regulating cell cycle progression by binding and activating cyclin-dependent kinases (CDK). Cyclin E1 protein, encoded by CCNE1, is an essential regulator of G1-to-S transition, and is also critical for DNA replication initiation. Cyclin E1 is a principal oncogenic driver, amplified in multiple cancers, including ovarian, endometrial, gastric and breast, and its expression in tumor cells is associated with poor prognosis. Therefore, in these areas of significant unmet medical need, selective elimination of cyclin E1 is expected to provide vital benefit to patients with aggressive malignancies. Once considered an “undruggable” cancer target by conventional small molecule inhibitor approaches, we have identified multiple MGD molecules that selectively degrade cyclin E1, and are in the process of optimizing the chemical leads. Cyclin E1 degrader represents a unique opportunity to expand the druggable target space and transform lives and outcomes for patients with devastating diseases.

In October 2023, Monte Rosa entered into a strategic collaboration and licensing agreement with Roche to discover and develop MGDs against targets in cancer and neurological diseases.